Marilina García, M. Redondo, I. Zarcos, J. Louro, F. Rivas-Ruíz, T. Téllez, Diego Pérez, F. Medina Cano, K. Machan, L. Domingo, Maria del Mar Vernet, M. Padilla-Ruiz, X. Castells, M. Sala
{"title":"Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program.","authors":"Marilina García, M. Redondo, I. Zarcos, J. Louro, F. Rivas-Ruíz, T. Téllez, Diego Pérez, F. Medina Cano, K. Machan, L. Domingo, Maria del Mar Vernet, M. Padilla-Ruiz, X. Castells, M. Sala","doi":"10.4274/ejbh.galenos.2022.2021-11-8","DOIUrl":null,"url":null,"abstract":"Objective\nThe aim of this study was to evaluate the existing survival rate and clinical-pathological differences among patients with breast cancer detected by mammographic screening.\n\n\nMaterials and Methods\nThis multicenter cohort study examined 1,248 patients who took part in a national screening program for the early detection of breast cancer over an eight-year period.\n\n\nResults\nOf the two patient subgroups (interval and screening), we found significant differences in the distribution of prognostic factors, with interval cases presenting at a lower mean age (p = 0.002), with higher percentages of human epidermal growth factor receptor 2 (HER-2) or triple negative and lower percentages of luminal A or luminal B carcinomas (p = 0.001), advanced stages (p<0.001), lower hormone receptor expression (p<0.001), poorer differentiation (p<0.001) and lower survival (p<0.001). Among the screening group, patients with tumors detected during the first screening round had a significantly lower mean age (p<0.001), a lower frequency of comorbidities (p = 0.038) and a lower tendency (p<0.1) to be diagnosed as triple negative breast carcinomas than incident cases.\n\n\nConclusion\nOur results highlight that breast tumors detected during the first screening round are frequently characterized by a more benign phenotype than the rest of the screening subgroups, which could be of help when stratifying the risk of death and selecting the best treatment option for each patient.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of breast health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/ejbh.galenos.2022.2021-11-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Objective
The aim of this study was to evaluate the existing survival rate and clinical-pathological differences among patients with breast cancer detected by mammographic screening.
Materials and Methods
This multicenter cohort study examined 1,248 patients who took part in a national screening program for the early detection of breast cancer over an eight-year period.
Results
Of the two patient subgroups (interval and screening), we found significant differences in the distribution of prognostic factors, with interval cases presenting at a lower mean age (p = 0.002), with higher percentages of human epidermal growth factor receptor 2 (HER-2) or triple negative and lower percentages of luminal A or luminal B carcinomas (p = 0.001), advanced stages (p<0.001), lower hormone receptor expression (p<0.001), poorer differentiation (p<0.001) and lower survival (p<0.001). Among the screening group, patients with tumors detected during the first screening round had a significantly lower mean age (p<0.001), a lower frequency of comorbidities (p = 0.038) and a lower tendency (p<0.1) to be diagnosed as triple negative breast carcinomas than incident cases.
Conclusion
Our results highlight that breast tumors detected during the first screening round are frequently characterized by a more benign phenotype than the rest of the screening subgroups, which could be of help when stratifying the risk of death and selecting the best treatment option for each patient.